Amicus Therapeutics competitors

Zippia score 4.6

Amicus Therapeutics main competitors are Gilead Sciences, Genentech, and Onyx Pharmaceuticals.

Competitor Summary. See how Amicus Therapeutics compares to its main competitors:

Merck has the most employees (74,000).
Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
The oldest company is Merck, founded in 1891.

Work at Amicus Therapeutics?

Share your experience

Amicus Therapeutics vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Amicus Therapeutics	2002	4.6	Cranbury, NJ	2	$528.3M	508
Regeneron	1988	4.9	Tarrytown, NY	7	$14.2B	9,123
Seagen	1997	4.7	Bothell, WA	3	$2.0B	900
Gilead Sciences	1987	4.5	Foster City, CA	9	$28.8B	11,800
Sanofi Genzyme	1981	4.8	Cambridge, MA	1	$4.6B	12,000
Amgen	1980	4.8	Thousand Oaks, CA	9	$33.4B	22,000
Merck	1891	4.6	Kenilworth, NJ	31	$64.2B	74,000
Medivation	2003	4.8	San Francisco, CA	1	$1.0B	628
Ariad Pharmaceuticals	1991	4.8	Cambridge, MA	1	$118.8M	380
Astellas Gene Therapies	2012	4.4	San Francisco, CA	1	$6.0M	76
BioMarin	1997	4.6	San Rafael, CA	4	$2.9B	2,581
Genentech	1976	4.5	South San Francisco, CA	5	$166.9M	13,638
Peregrine Pharmaceuticals	1981	4.6	Tustin, CA	1	$57.6M	321
Onyx Pharmaceuticals	1992	4.8	South San Francisco, CA	2	$362.2M	500
PDL BioPharma	1986	4.2	Incline Village, NV	1	$30.7M	75
Centocor	1979	4.1	Malvern, PA	1	$110.0M	3,000
American Air Liquide Holdings	1902	4.8	Houston, TX	7	$5.3B	8,197
Morphotek	2000	3.7	Exton, PA	1	$4.8M	1

Rate how well Amicus Therapeutics differentiates itself from its competitors.

Amicus Therapeutics salaries vs competitors

Among Amicus Therapeutics competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare Amicus Therapeutics salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Amicus Therapeutics	$88,124	$42.37	-
Regeneron	$85,589	$41.15	-
Seagen	$85,008	$40.87	-
Gilead Sciences	$99,828	$47.99	-
Sanofi Genzyme	$84,495	$40.62	-
Amgen	$93,349	$44.88	-

Compare Amicus Therapeutics job title salaries vs competitors

Company	Highest salary	Hourly salary
Amicus Therapeutics	$79,408	$38.18
Genentech	$105,893	$50.91
BioMarin	$94,417	$45.39
Onyx Pharmaceuticals	$94,176	$45.28
American Air Liquide Holdings	$92,562	$44.50
Amgen	$90,566	$43.54
Ariad Pharmaceuticals	$88,730	$42.66
Regeneron	$88,568	$42.58
Sanofi Genzyme	$86,873	$41.77
Merck	$85,831	$41.26
Medivation	$83,769	$40.27
Gilead Sciences	$83,237	$40.02
Centocor	$79,793	$38.36
Seagen	$75,540	$36.32
PDL BioPharma	$74,489	$35.81
Morphotek	$70,796	$34.04
Peregrine Pharmaceuticals	$70,497	$33.89
Astellas Gene Therapies	$63,983	$30.76

Do you work at Amicus Therapeutics?

Does Amicus Therapeutics effectively differentiate itself from competitors?

Amicus Therapeutics jobs

Amicus Therapeutics demographics vs competitors

Compare gender at Amicus Therapeutics vs competitors

Job title	Male	Female
Amicus Therapeutics	43%	57%
PDL BioPharma	46%	54%
BioMarin	50%	50%
Merck	54%	46%
Gilead Sciences	56%	44%
Amgen	57%	43%

Male

Female

100%

75%

50%

25%

25%

50%

75%

100%

Compare race at Amicus Therapeutics vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Amicus Therapeutics	47%	17%	9%	21%	6%	8.8
Amgen	49%	24%	7%	15%	5%	9.7
BioMarin	43%	20%	8%	23%	7%	9.6
Gilead Sciences	44%	20%	8%	23%	6%	9.8
Merck	56%	16%	10%	14%	4%	9.8
PDL BioPharma	54%	15%	7%	19%	4%	9.3

Amicus Therapeutics revenue vs competitors

Amicus Therapeutics revenue is $528.3M. Among it's competitors, the company with the highest revenue is Merck, $64.2B . The company with the lowest revenue is Morphotek, $4.8M.

Amicus Therapeutics and similar companies CEOs

CEOBio

Robert A. Bradway

Amgen

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Jean Jacques Bienaime

BioMarin

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Daniel O’Day

Gilead Sciences

Robert M. Davis

Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Christopher Stone

PDL BioPharma

Nicholas Green

Peregrine Pharmaceuticals

Roger D. Dansey

Seagen

François Jackow

American Air Liquide Holdings

Alexander Hardy

Genentech

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Paul Hudson

Sanofi Genzyme